Articles from Applied Biologics

SCOTTSDALE, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the extension of its longstanding system-wide purchase agreement with Providence Health & Services for XWRAP®. The agreement reinforces the Company’s ongoing relationship with one of the nation’s largest integrated health systems and supports continued access to XWRAP across participating Providence facilities and affiliated organizations.

SCOTTSDALE, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the initiation of a multi-center retrospective real-world outcomes study evaluating the clinical performance of XWRAP® in routine wound care practice.

SCOTTSDALE, Ariz., July 20, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced submission of a scientific abstract describing new translational research involving XWRAP® for consideration at the Symposium on Advanced Wound Care (SAWC) Fall 2026.

SCOTTSDALE, Ariz., July 14, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the successful manufacture of the first research construct for its preclinical Disease-Modifying Osteoarthritis (DMOAD) Gene Therapy Program.

SCOTTSDALE, Ariz., July 09, 2026 (GLOBE NEWSWIRE) -- Following the recent publication of translational research demonstrating that tissue processing methodologies can influence biologic outcomes, Applied Biologics today formally introduced ECM Preservation Technology™ (EPT™) as the proprietary manufacturing platform used in the production of XWRAP®, the Company’s placental-derived wound cover for chronic wounds and tissue-plane barrier for surgical procedures.

SCOTTSDALE, Ariz., July 07, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced that the U.S. Department of Veterans Affairs (VA) has initiated an administrative modification to transition the Company’s Federal Supply Schedule (FSS) contract to the VA’s updated Evergreen contract structure. Upon execution of the administrative modification, the contract structure will transition from a five-year base period with one five-year option period to a five-year base period with three five-year option periods. Subject to the Government’s future exercise of those option periods in accordance with the contract, the updated structure provides the potential for continued availability of XWRAP® through the VA Federal Supply Schedule for up to 20 years.

SCOTTSDALE, Ariz., July 01, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced an expanded strategic initiative focused on advancing the use of XWRAP® across surgical applications.

SCOTTSDALE, Ariz., June 30, 2026 (GLOBE NEWSWIRE) -- Applied Biologics today announced the expansion of its national commercial organization as the Company continues to support growing demand for XWRAP® while preparing for the future commercialization of its expanding regenerative medicine pipeline.

SCOTTSDALE, Ariz., June 24, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced completion of a translational research study evaluating the impact of placental tissue processing methodologies on wound healing biology.

SCOTTSDALE, Ariz, June 23, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the submission of an abstract titled “Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of the CAMPX Trial” to the Symposium on Advanced Wound Care (SAWC) Fall 2026.

SCOTTSDALE, Ariz., June 17, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the completion of planned enrollment activities in the CAMPX randomized controlled clinical trial evaluating XWRAP® in the treatment of chronic diabetic foot ulcers.

SCOTTSDALE, Ariz., June 15, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced positive findings from updated analyses of the ongoing CAMPX randomized controlled clinical trial evaluating XWRAP® in the treatment of chronic diabetic foot ulcers.

SCOTTSDALE, Ariz., June 11, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the initiation of a preclinical research program focused on osteoarthritis and other degenerative diseases.

Interim Findings from Prospective Randomized Controlled Trial of XWRAP® Support Continued Enrollment in Chronic Diabetic Foot Ulcer Study

SCOTTSDALE, Ariz., June 09, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company developing novel biologic therapies for chronic wounds, tissue repair, and degenerative disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for BIOxHEAL, enabling advancement into Phase 3 clinical development for the treatment of diabetic foot ulcers (DFU).